In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Betting big on talent, resources, and the ecosystem required for innovation and enterprise, Prime Minister Narendra Modi invited stakeholders to ideate in India, innovate in India and Make in India for the world
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
The pharma park will be built at an estimated cost of Rs 34.94 crore and will be spread over 50 acres at Chanho close to Ranchi
The division will focus on products that are required during ophthalmic surgical procedures like cataracts and refractive surgeries among others
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
